通心痹合剂对冠心病心绞痛患者血管内皮损伤影响临床研究.docVIP

通心痹合剂对冠心病心绞痛患者血管内皮损伤影响临床研究 　　摘要：目的 观察中药“通心痹合剂”治疗冠状动脉粥样硬化性心脏病（CHD、简称冠心病）心绞痛患者的临床疗效及改善内皮细胞损伤、抑制血小板活化、抗炎症反应的影响。方法 选择60例符合条件的CHD心绞痛患者，应用随机数字表法分入治疗组和对照组各30例。治疗组在基础治疗上加用中药“通心痹合剂”口服，对照组在基础治疗上加用“心可舒”片，每次4片，每日3次，2组均连续服药4周为1个疗程，观察CHD心绞痛患者临床症状及血浆血管性假性血友病因子（vWF）、α颗粒膜蛋白140（GMP-140）、血清C反应蛋白（CRP）和肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）治疗前后水平变化。结果 （1）治疗组总有效率9333%，明显高于对照组8333%，且能显著缓解冠心病心绞痛发作；（2）治疗组vWF、GMP-140、CRP、TNF-α、IL-6含量均明显低于对照组（P005，P001）；结论 中药“通心痹合剂”治疗CHD心绞痛疗效确切，可显著改善心绞痛发作；其机理可能改善其内皮细胞损伤、抑制血小板活化、抗动脉炎症反应、从而达到治疗CHD的目的。 　　关键词：通心痹合剂；CHD心绞痛；vWF；GMP-140；CRP；TNF-α；IL-6 　　中图分类号：R2562 文献标志码：A 文章编号：1007-2349（2016）08-0024-04 　　【Abstract】Objective：To observe the clinical effect ofTongxinbihe Mixture on the treatment of coronary atherosclerotic heart disease（CHD）patients with angina pectoris and the improvement of endothelial cell injury，platelet activation inhibition and anti-inflammatory responseMethods：60 patients were randomly divided into a treatment group and a control group，30 cases per groupThe treatment group was added oralTongxinbihe Mixture besides basic treatment while the control group was added Xinkeshu tablets，4 pc each，3 times daily besides basic treatmentThe two groups were given continuous medication for 4 weeks，a course of treatment，and the clinical symptoms，plasma von Willebrand factor（vWF），α-granule membrane protein 140（GMP-140），serum C-reactive protein（CRP）and tumor necrosis factor α（TNF- α），interleukin-6（IL-6）levels of the patients were observed before and after the treatmentResults：The total curative effect rate of the treatment group was 9333%，significantly higher than the rate（8333%）of the control group，and could significantly relieve angina pectoris attackThe vWF，GMP-140，CRP，TNF-α and IL-6 of the treatment group were significantly lower than those of the control group（P005，P 　　【Key words】Tongxinbihe Mixture，CHD angina，vWF，GMP-140，CRP，TNF-α，IL-6 　　冠心病（CHD）是严重危害人类健康的疾病之一，其发病率呈逐年增加的趋势，研究表明，血管内皮损伤和血小板活化在冠心病血栓形成过程中起着重要的作用。笔者前期临床研究证实[1]，中药“通心痹合剂”具有抗炎症反应、调节脂质代谢、防治动脉粥样硬化（AS）